Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)    
Revenues
Operating expenses:    
General and administrative 157,047 52,602
Stock-based compensation expense 41,302
Management salaries and consulting fees 163,275 16,412
Research and development 67,710 0
Total operating expenses 429,334 69,014
Loss from operations (429,334) (69,014)
Other income (expense):    
Gain on extinguishment and forgiveness of debt, net 28,568 0
Loss on fair value adjustment - derivatives (700) (800)
Interest expense (48,234) (63,886)
Amortization of interest - beneficial conversion feature (174) (5,356)
Total other income (expense) (20,540) (70,042)
Loss before provision for income taxes (449,874) (139,056)
Provision for income taxes
Net loss (449,874) (139,056)
Net (income) loss attributable to noncontrolling interest (149) 767
Net loss attributable to TransBiotec, Inc. $ (450,023) $ (138,289)
Net loss per share    
(Basic and fully diluted) $ (0.002) $ (0.001)
Weighted average number of common shares outstanding 254,048,982 130,145,018